Teva’s Antibody Protected the Gut From Gluten in a Celiac Disease Trial

People with celiac disease have exactly one option: a lifelong, strict gluten-free diet. There is no approved drug. Teva has early data suggesting that might change.

In a Phase 2a study, TEV-408 — an anti-IL-15 antibody designed for quarterly dosing — produced a “statistically significant and clinically meaningful” reduction in gluten-induced intestinal damage versus placebo over eight weeks.

What celiac disease actually is

Celiac is not an allergy or an intolerance. It is an autoimmune disease triggered by a specific dietary protein.

In genetically susceptible people, fragments of gluten that survive digestion cross into the intestinal lining, where they are modified by an enzyme and then presented to the immune system. That triggers a T-cell response against the tissue itself. The result is progressive damage to the villi, the finger-like projections that provide the small intestine’s absorptive surface. As they flatten, nutrient absorption fails — producing anaemia, bone disease, growth failure in children, and a raised risk of certain intestinal cancers over time.

Why IL-15 is the target

IL-15 is a signalling protein that occupies an unusually central position in this process. It is elevated in the celiac intestine and drives activation of intraepithelial lymphocytes — immune cells resident in the gut lining — converting them into cells that kill the epithelial cells around them.

IL-15 sits close to the tissue damage rather than at the start of the cascade, which is strategically useful. Blocking it does not stop the immune system from recognising gluten; it aims to prevent that recognition from translating into destroyed villi. A patient would still have celiac disease, but incidental exposure would do less harm.

Why the endpoint matters

The trial measured gluten-induced intestinal damage rather than symptoms, and that is the right choice.

Celiac symptoms correlate poorly with intestinal injury — a substantial proportion of patients have significant villous damage with minimal symptoms, which is exactly why the disease causes long-term harm in people who feel adequately well. Symptom scores are also subjective and prone to placebo response. Measuring the tissue tests whether the drug does the thing that matters.

The problem this would solve

The gluten-free diet is genuinely effective when followed perfectly. Perfection is the difficulty.

Gluten appears in unexpected products, cross-contamination in shared kitchens and restaurants is routine, and labelling varies. Studies of well-motivated patients consistently find ongoing exposure and persistent intestinal damage despite serious dietary effort. There is also a substantial burden that rarely appears in clinical measures: the vigilance, the social constraint, the cost of specialty foods.

A drug blunting the damage from incidental exposure — not licensing a return to eating bread, but making an unavoidable mistake less consequential — would meaningfully change how the disease is lived with. Celiac affects roughly 1% of people, so the addressable population is large.

A field with a difficult record

Caution is warranted, because several plausible celiac therapies have failed at exactly this stage. Approaches aimed at tightening the intestinal barrier, at enzymatically degrading gluten before it can be recognised, and at inducing immune tolerance have all reached clinical trials and disappointed.

The recurring problem is that the cascade has redundancy: blocking one step often fails to prevent the outcome. Whether IL-15 blockade is different — whether it sits at a genuine bottleneck — is precisely what larger trials must establish.

The pipeline-in-a-product claim

Teva describes TEV-408 as having “pipeline-in-a-product” potential — the same drug working across several immune conditions — supported by encouraging Phase 1b results in vitiligo.

The vitiligo connection is not arbitrary. In vitiligo the immune system destroys pigment-producing cells in the skin, and IL-15 signalling has been implicated in maintaining the tissue-resident memory T cells that drive it. Two diseases, different organs, same signalling axis. If IL-15 blockade works in both, it validates the mechanism rather than a single indication — which is what makes the asset strategically interesting to Teva.

How early this is

Phase 2a, eight weeks. That establishes a biological effect in a small population over a short period. It does not establish durability, whether protection holds against larger or repeated gluten exposure, or safety over the years a chronic therapy would require.

The safety question deserves attention: IL-15 has roles in normal immune function, including in natural killer cells and immune surveillance. Blocking it quarterly for decades is a different proposition from doing so for eight weeks.

Why quarterly dosing is a deliberate design choice

The dosing interval is easy to skim past and is in fact central to whether this drug could work commercially.

Celiac disease is managed, today, for free. A diet costs nothing in prescription terms, and patients who follow it carefully are often genuinely well. Any drug therefore competes not against another medicine but against an effective intervention with no drug price and no injection — a demanding comparator.

That sets a high bar for convenience. A daily tablet or a frequent injection layered on top of a diet patients must still follow would face real adherence problems for a condition that, between exposures, produces no symptoms to remind anyone. Four injections a year is a materially different proposition — closer to a background protective measure than a treatment regimen — and it fits how the drug would actually be used, guarding against exposures that are unpredictable rather than scheduled.

Further analyses from the ongoing Phase 2a are underway, with more results expected at a future medical meeting. Early clinical research; not medical advice, and no substitute for a gluten-free diet.